Almirall launches new call to find innovative therapies for skin diseases

BARCELONA, Spain. July 20, 2022 – Almirall, S.A. (ALM), a global biopharmaceutical company focused on skin health, today launched its 7th call through AlmirallShare, its open innovation platform, for proposals to establish collaborations in dermatological research. The aim of this year's edition is to find new partnership opportunities for assets in preclinical or clinical development stages that can become new treatments for skin diseases.

The proposals should focus on preclinical and clinical assets from any therapeutic modality, such as small molecules, biologics, or advanced therapies. The assets may have the potential to target immuno-inflammatory pathways for dermatological indications such as atopic dermatitis, hidradenitis suppurativa, alopecia areata or vitiligo; or be suitable for non-melanoma skin cancer such as basal and squamous cell carcinoma and cutaneous T cell lymphoma, or rare dermatological indications such as epidermolysis bullosa, pemphigus vulgaris, bullous pemphigoid, among others. For preclinical assets, compelling evidence of in vitro and in vivo efficacy will be highly valuable.

This year’s call is addressed to scientists affiliated with start-ups, biotech companies, pharmaceutical companies, universities, and research centres anywhere in the world, who can submit their proposals at sharedinnovation.almirall.com until October 31, 2022. A team of Almirall’s scientific experts will evaluate the submitted proposals to select those that better fit the call requirements and have the potential to establish a long-term business partnership with the company.

“Since its launch five years ago, AlmirallShare has consolidated its position as a powerful channel for scientific exchange and cross-functional collaboration. It has enabled us to forge unique and valuable alliances with scientists that have led to long-term relationships. With this new call for proposals, we want to continue fostering scientific creativity by bringing people and cultures from around the world to accelerate progress and drive the development of novel dermatological medical solutions,” stated Maribel Crespo, AlmirallShare Leader.

AlmirallShare, at the heart of research

AlmirallShare was launched in 2017 as an open innovation R&D platform designed to facilitate collaborations in dermatological research and find innovative solutions in medical dermatology. This initiative has drawn more than 1,100 scientists and received 560 proposals from up to 54 countries, proving to be a successful initiative that has allowed Almirall to gain increasing recognition from the scientific community, raising the company’s profile as a trusted partner for future collaborations.

Almirall has built unique and valuable collaborations through this open innovation platform with scientists, universities, public and private institutions, hospitals, and biotechnology companies. The company has established 8 collaborative projects with different institutions to date, including collaborations for new therapies (IDIBAPS, University of Turin, University of South Australia, Hospital de la Santa Creu i Sant Pau), new targets (Dublin City University, University of Namur), and new preclinical models (University College Dublin, University of Sheffield).

About Almirall

Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient’s needs through science to improve their lives.  Our Noble Purpose is at the core of our work: “Transform the patients' world by helping them realize their hopes and dreams for a healthy life”. We invest in differentiated and ground-breaking medical dermatology products to bring our innovative solutions to patients in need.

The company, founded in 1943 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM). Throughout its 79-year history, Almirall has retained a strong focus on the needs of patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, with about 1,800 employees. Total revenues in 2021 were 836.5 million euros.

For more information, please visit almirall.com